ARWR logo

Arrowhead Pharmaceuticals, Inc.

ARWR
Healthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Jan 9, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (14)

Dec 2026
Est. completion
P1Spinocerebellar Ataxia Type 2
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Feb 2027
Est. completion
P1P2Obesity
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Jun 2027
Est. completion
P1P2Alzheimer Disease
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Jun 2027
Est. completion
NAOpioid Use Disorder
Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
Jul 2027
Est. completion
P1P2Hyperlipidemia; Mixed
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Aug 2027
Est. completion
P3Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Oct 2027
Est. completion
P1P2Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Dec 2027
Est. completion
P2Asthma
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Mar 2028
Est. completion
NADepression, Unipolar
Maternal Mindfulness: Depression and Postpartum Pain
Jul 2028
Est. completion
P1Age-related Macular Degeneration
A First-In-Human Study of ARO-033 in Adult Participants
Jul 2028
Est. completion
P3Hypertriglyceridemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Jul 2028
Est. completion
P3Homozygous Familial Hypercholesterolemia
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Dec 2028
Est. completion
P3Intracerebral Hemorrhage
Statins In Intracerbral Hemorrhage
Mar 2029
Est. completion
P3Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Recent Press Releases

SEC Filings (69)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Aug 4, 202610-QQuarterly reportDocumentIndex
Jul 31, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
May 7, 2026S-8Employee stock planDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
May 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 24, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 20, 20268-KMaterial eventDocumentIndex
Feb 5, 202610-QQuarterly reportDocumentIndex
Feb 5, 20268-KMaterial eventDocumentIndex
Jan 27, 2026ARSAnnual report to holdersDocumentIndex
Jan 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jan 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Jan 9, 20268-KMaterial eventDocumentIndex
Jan 9, 2026424B5Offering prospectusDocumentIndex
Jan 9, 2026424B5Offering prospectusDocumentIndex
Jan 8, 2026305B2DocumentIndex
Jan 8, 2026FWPDocumentIndex
Jan 8, 2026FWPDocumentIndex
Jan 7, 2026424B5Offering prospectusDocumentIndex
Jan 7, 2026424B5Offering prospectusDocumentIndex
Jan 6, 20268-KMaterial eventDocumentIndex
Dec 11, 2025S-3ASRShelf registrationDocumentIndex
Nov 25, 202510-KAnnual reportDocumentIndex
Nov 25, 20258-KMaterial eventDocumentIndex
Nov 18, 20258-KMaterial eventDocumentIndex
Oct 10, 202510-K/AAnnual reportDocumentIndex
Sep 12, 20258-KMaterial eventDocumentIndex
Sep 11, 20258-KMaterial eventDocumentIndex